EPS: As of FY2025 Q1, the actual value is USD -0.42.

EBIT: As of FY2025 Q1, the actual value is USD -15.56 M.

Operational Metrics

• Net Loss: The net loss for the three months ended March 31, 2025 was $15,941,328, compared to $230,970 for the same period in 2024, reflecting an increase of $15,710,358.
• General and Administrative Expenses: Increased to $15,073,548 for the three months ended March 31, 2025, from $132,804 for the same period in 2024, primarily due to stock-based compensation and increased professional services.
• Research and Development Expenses: Increased to $263,093 for the three months ended March 31, 2025, from $10,500 for the same period in 2024.
• Sales and Marketing Expenses: Increased to $219,839 for the three months ended March 31, 2025, from $87,666 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: $1,751,528 for the three months ended March 31, 2025, compared to $192,971 for the same period in 2024.
• Net Cash Provided by Financing Activities: $3,094,438 for the three months ended March 31, 2025, compared to $229,084 for the same period in 2024.

Unique Metrics

• Convertible Notes: Convertible notes valued at $3,175,354 as of March 31, 2025.

Future Outlook and Strategy

• Core Business Focus: Aspire plans to generate revenue through developing and marketing drugs and nutraceuticals using novel sublingual delivery technology. The company is conducting clinical trials for its high-dose sublingual aspirin product, aiming for FDA approval by June 30, 2025.
• Non-Core Business: Aspire is developing other products such as sublingual melatonin, vitamins, testosterone, semaglutide, and caffeine products, with plans to launch some by July 1, 2025.
• Priority: Aspire intends to raise additional capital through equity issuances to support its growth and development efforts.